Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $67.41M rose 7.1% year over year, behind the +31.2% change in trailing-twelve-month research & development. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +43.9% a year.

Context

  • Research & development amounted to 16340.0% of revenue in FY2025, up 14010.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.1% toward the trailing-twelve-month pace of +31.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$67.41M-0.2% QoQ
Last fiscal yearDec 2025
$245.1M+49.9% YoY
LTMSep 2026
$283.32M+31.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.1%——
1 year+49.9%——
3-year CAGR+43.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
245.1M USD
Year-over-year change
+49.9%
4-year CAGR
+44.1%

Research & Development vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 research & development of $283.32M is the 3rd highest of the 10 companies compared; the peer median is $135.36M.
  • Its year-over-year change of +31.2% is the 2nd highest of 9, against a peer median of +6.4%.
  • Research & development amounts to 252960.7% of revenue for CLDX, versus a peer median of 86.2%.
CLDX Competitors Peer median
Research & Development for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$497M +2.5%+22.0%424.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M +31.2%+43.9%252960.7%
XNCRXencor, Inc.LTM Jun 2026$255.77M +11.4%+6.3%243.6%
IMNMImmunome, Inc.LTM Sep 2026$236.54M +35.6%+95.7%—
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
CGENCompugen Ltd.LTM Mar 2026$23.92M -1.0%-9.4%32.9%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $135.36M+6.4%+12.5%86.2%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.